A Phase 2 interventional study of SKB571 for injection in Gastrointestinal Tumors, sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.. Recruiting at 26 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Digestive System Neoplasms with a site in China — 35 open to participants now, 40 under way, 4 of them phase 3. Digestive System Neoplasms · China.
Among the 75 studies in Digestive System Neoplasms with a site in China, this one is the 19th largest by planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2026, is one of 21 in phase 2, reaches primary completion later than 22 of the 39 other live ones, and was the 70th registered.
195 studies on the registry are indexed under Digestive System Neoplasms; 57 are open to participants now.
Browse Digestive System Neoplasms studies →35 of the 75 studies in Digestive System Neoplasms with a site in China are open now. Recruiting first, the newest first:
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Xijing Hospital · Sites in China
Ages 45–74 · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 52 Digestive System Neoplasms studies recruiting now, 27 (52%) set no upper age limit and 17 (33%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 27 · Phase 3 10
First in 2008; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 50 across 156 interventional studies indexed under Digestive System Neoplasms.
Median enrollment 60 across the 64 interventional studies, 300 across the 11 observational. Of the 20 that completed or were terminated, 5 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., one of the names counted as Sichuan Kelun Pharmaceutical Co.,Ltd.. Under that name alone:
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is the lead sponsor of 55 studies on the registry; 33 are open to participants now.
Sichuan Kelun Pharmaceutical Co.,Ltd. has 1 study filed under Digestive System Neoplasms — fewer than ten, so there is no comparison to draw.
14 of the studies in Digestive System Neoplasms with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT05252078Jiangxi Provincial Cancer HospitalAnlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients | 2026-11 |
| NCT05262491Sichuan Baili Pharmaceutical Co., Ltd.A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor | 2026-12 |
| NCT06881043The First Hospital of Jilin UniversityThe Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer | 2026-12-01 |
| NCT06099821Peking University Cancer Hospital & InstituteKN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 75 studies in Digestive System Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 in participants with gastrointestinal tumors.
This is a multicenter, open-label, Phase II clinical study to evaluate the efficacy, safety, tolerability, PK characteristics, and immunogenicity of SKB571 in participants with gastrointestinal tumors. Approximately 120 subjects will be enrolled in this study, including 4 cohorts with approximately 20-30 participants enrolled in each cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: SKB571 for injection
Drug: SKB571 for injection
Drug: SKB571 for injection
Drug: SKB571 for injection
Drug: SKB571 for injection
Intravenous(IV) infusion(Q3W)
Objective response rate (ORR)
Time frame: Up to approximately 24 months
Progression-free survival (PFS), duration of response (DOR), disease control rate (DCR), and overall survival (OS)
Time frame: Up to approximately 24 months
Safety and tolerability
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (based on CTCAE v6.0), clinically significant abnormal laboratory test results, etc.
Time frame: Up to approximately 24 months
Maximum Plasma Concentration (Cmax) of SKB571-ADC
Blood Samples will be collected to determine the Cmax of SKB571-ADC in the plasma
Time frame: Up to approximately 24 months
Immunogenicity
Blood Samples will be collected to measure Anti-drug antibody (ADA) against SKB571 in the serum
Time frame: Up to approximately 24 months
Minimum Plasma Concentration(Cmin) of SKB571-ADC
Blood samples will be collected to determine the Cmin of SKB571-ADC in the plasma
Time frame: Up to approximately 24 months
Maximum Plasma Concentration(Cmax) of SKB571-TAb
Blood samples will be collected to determine the Cmax of SKB571-TAb in the plasma
Time frame: Up to approximately 24 months
Minimum Plasma Concentration(Cmin) of SKB571-TAb
Blood Samples will be collected to determine the Cmin of SKB571-TAb in the plasma
Time frame: Up to approximately 24 months
Maximum Plasma Concentration (Cmax) of unconjugated KL610348
Blood Samples will be collected to determine the Cmax of unconjugated KL610348 in the plasma
Time frame: Up to approximately 24 months
Minimum Plasma Concentration(Cmin) of unconjugated KL610348
Blood Samples will be collected to determine the Cmin of unconjugated KL610348 in the plasma
Time frame: Up to approximately 24 months
Correlation between biomarkers and efficacy
To evaluate the correlation between the expression levels of tumor-related genes in tumor tissues and efficacy
Time frame: Up to approximately 24 months
Started May 2026 (actual). Primary completion is estimated for Aug 2027, 15 months after the start.
Of 29 phase 2 interventional studies under Digestive System Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's planned 15 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SKB571
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. →